4-methyl-5-butylimidazole | 45771-62-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-methyl-5-butylimidazole
• 英文别名: 4-butyl-5-methyl-1H-imidazole
• CAS: 45771-62-8
• 化学式: C₈H₁₄N₂
• mdl: MFCD20617764
• 分子量: 138.213
• InChiKey: AGTZLDHZROZIDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-庚酮 在 三氟化硼乙醚 、 溴 、 silica gel 作用下， 以 乙酸乙酯 为溶剂， 反应 7.0h， 生成 4-methyl-5-butylimidazole
  参考文献：
  名称：

  Synthesis of imidazoles

  摘要：

  Silica gel was found to facilitate the conversion of 3-bromo-2-alkanones to imidazoles by the action of formamide. The selective 3-bromination of 2-alkanones was carried out in ethyl acetate.

  DOI：

  10.1007/bf00965449

文献信息

• Purine Derivatives as Agonists of the Adenosine A2a Receptor
  申请人：Allen David George

  公开号：US20080214581A1

  公开（公告）日：2008-09-04

  A compound of formula (I): wherein R 1 -R 3 are as defined in the specification, and compositions, combinations, and methods of manufacture, and methods of treatment of inflammatory diseases, using the same.

  化合物式(I)：其中R1-R3的定义如规范所述，以及使用该化合物的组合物、组合物和制造方法以及治疗炎症性疾病的方法。
• Inhibitors of Akt Activity
  申请人：Bilodeau Mark T.

  公开号：US20080280899A1

  公开（公告）日：2008-11-13

  The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.

  本发明涉及含有取代萘啶的化合物，其抑制Akt，一种丝氨酸/苏氨酸蛋白激酶的活性。本发明还涉及包含该发明化合物的化疗组合物以及使用该发明化合物治疗癌症的方法。
• One-Pot Syntheses of Substituted Oxazoles and Imidazoles from the Isocyanide Asmic
  作者：Louis G. Mueller、Taylor M. Keller、Fraser F. Fleming

  DOI：10.1021/acs.joc.2c02290

  日期：2023.1.20

  Substituted oxazoles and imidazoles are synthesized in one pot from the isocyanide building block Asmic (anisylsulfanylmethyl isocyanide), an alkyl halide, and an acid chloride or nitrile, respectively. The modular assembly employs sequential deprotonation–alkylation and deprotonation–acylation or imination of Asmic, followed by an unusual carbon–sulfur bond cleavage to construct the azole. The strategy

  取代的恶唑和咪唑分别由异氰化物结构单元 Asmic（茴硫基甲基异氰化物）、卤代烷和酰氯或腈在一个锅中合成。模块化组装采用 Asmic 的连续去质子化-烷基化和去质子化-酰化或亚胺化，然后是不寻常的碳-硫键裂解来构建唑。该策略稳健、高效，并在一次操作中提供 C4-C5 双取代恶唑或咪唑
• Novel synthesis of N-unsubsdtituted imidazoles using N-trimethylsilylimines
  作者：Neng-Yang Shih

  DOI：10.1016/s0040-4039(00)61628-3

  日期：1993.1

  Cycloaddition of N-trimethylsilylimines 3 with the lithiotosylmethylisocyanates 4 is described. This provides a novel synthesis of 4-substituted and 4,5-disubstituted imidazoles from easily accessible aldehydes or organolithium reagents, under mild conditions and in a one-pot operation.
• ZAVYALOV, S. I.;EZHOVA, G. I.;SITKAREVA, I. V., IZV. AN CCCP. CEP. XIM.,(1991) N, S. 511-513
  作者：ZAVYALOV, S. I.、EZHOVA, G. I.、SITKAREVA, I. V.

  DOI：——

  日期：——